4 hrs ago | Zacks Analyst Blog
United Thera Expecting Too Much
Although the current business fundamentals at United Therapeutics Corp. are solid, we are seeing several potential hiccups coming in the next year.
United Therapeutics Corporation Q2 2008 Earnings Call Transcript
Bret Holley - ' Oppenheimer & Co. Matthew Kaplan - ' Ladenburg Thalmann & Co. Lucy Lu - ' Citigroup Liana Moussatos - ' Pacific Growth Equities Presentation Operator Good morning, my name is Tim and I will be ...
New Drug Application For Inhaled Treprostinil Submitted To The U.S. Food And Drug Administration
Clinical Trials / Drug Trials United Therapeutics Corporation and its wholly-owned subsidiary, Lung Rx, Inc., announced the submission of a New Drug Application to the U.S. Food and Drug Administration for ...
United Therapeutics shares rise on Viveta data
Shares of United Therapeutics Corp. rose Thursday after data showed that an inhaled version of its drug candidate to treat pulmonary arterial hypertension met its goal in a late-stage trial.
Movers roundup: Moody's, PetSmart
Shares of United Therapeutics Corp. rose Thursday after data showed that an inhaled version of its drug candidate to treat pulmonary arterial hypertension met its goal in a late-stage trial.
Earnings: Dominion, United Therapeutics, Vanda
Revenue fell 6 percent, to $4.39 billion. The company attributed results to deferred fuel expenses that weighed down the year-ago period, a growing merchant generation business, higher production and prices ... via The Washington Post
United Therapeutics Corp. Q1 2008 Earnings Call Transcript
Martine A. Rothblatt Ph.D. - Chairman of the Board, CEO Roger Jeffs Ph.D. - President, COO, Director John M. Ferrari Ph.D. - CFO, Treasurer Analysts Brent Holly - Oppenheimer & Co Phil Nadeau - Cowen and ... via Seeking Alpha
United Therapeutics profit falls short of Street
United Therapeutics Corp. 's top line grew 55 percent in the first quarter on the growth in sales of its lead product, Remodulin, which treats pulmonary hypertension, but the company failed to hit the Wall ... via Triangle Business Journal
DPR Construction launches Raleigh-Durham ops with Bovis Lend Lease veteran
Redwood City, Calif.-based DPR Construction Inc. , one of the largest general contracting firms in the country, is establishing a beachhead in the Triangle. via Construction News
Martine Rothblatt founded Sirius Satellite Radio from a desire to link people together. via WTOP-FM Washington
Business is personal for satellite radio, drug entrepreneur
“She was an innovative thinker, while not an outlandish one ... just spinning science fiction”
Martine Rothblatt founded Sirius Satellite Radio from a desire to link people together. via SiliconValley.com
United Therapeutics' inhaled treprostinil may have limited efficacy...
“Maybe they needed too many patients to prove that this improvement was real and not just by chance”
Pharmawire - 'a news service focused on providing insight into the most price sensitive issues in the global pharmaceutical market. via Financial Times
United Therapeutics Chief Executive Martine A. Rothblatt Exercises Options for 8,200 Shares
The chief executive of biotechnology company United Therapeutics Corp. exercises options for 8,200 shares of stock under a prearranged trading plan, according to a Securities and Exchange Commission filing. via Canadian Business Magazine
Jay Hancock: A Md. firm ups the spin on its CEO's huge payday
“We feel there's probably no better way to give her incentive compensation that's better aligned with shareholder interests.”
The requirement for public companies to include stock options in reported costs is two years old. via The Baltimore Sun
United Therapeutics earns less United Therapeutics Corp., of Silver Spring, which develops pharmaceuticals to treat cardiovascular, infectious and oncological diseases, said fourth-quarter profit fell 96 ... via Daily Record
United Therapeutics Reports Fourth Quarter and Annual 2007 Financial Results
“We are pleased to report that United Therapeutics' revenues for the year ended December 31, 2007, totaled $210.9 million”
United Therapeutics Corporation today announced financial results for the fourth quarter and year ended December 31, 2007. via Med Ad News
The prescription benefits manager said Q4 EPS was flat at 43 cents ex items, beating views by 2 cents. via Investor's Business Daily
Sales up, profits down at United Therapeutics
Washington Business Journal - by Tucker Echols Staff Reporter Earnings fell 96 percent at United Therapeutics last quarter, weighed down by the cost of stock options and fewer tax benefits than a year ago. via Washington Business Journal
Research and Markets: Obtain up to Date Company Information on United Therapeutics Corporation
This profile is an essential source for company data and information. The profile examines United Therapeutics Corporation's key business structure and operations, history and products, and provides summary ... via PR-inside.com
United Therapeutics CEO Martine A. Rothblatt Exercises Options for 7,200 Shares
The chief executive of biotechnology company United Therapeutics Corp. exercised options for 7,200 shares of common stock under a prearranged trading plan, according to a Securities and Exchange Commission ... via Canadian Business Magazine